Chondrosarcoma: Ivosidenib Treatment Study

We are studying the effects of ivosidenib in adults with locally advanced or metastatic chondrosarcoma. This trial aims to see if it improves tumor outcomes and overall survival compared to standard treatments.

>2 yearsConfirmation phase (III)Partially RemoteInvestigational MedicinesOralOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ivosidenib
Ivosidenib is a cancer-targeting substance used to treat cancers that have an IDH1 gene mutation, especially acute myeloid leukemia.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Ivosidenib
AG-120

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Universitair Ziekenhuis Gent
Poli Dagkliniek, Medische Oncologie
Ledeberg, Belgium
Cliniques Universitaires Saint-Luc
Medical Oncology
Sint-Stevens-Woluwe, Belgium
Centre hospitalier universitaire de Liege
Medical Oncology
Tilff, Belgium
Sponsor: Institut De Recherches Internationales Servier IRIS
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.